Background: Prostate cancer (PCa) is a significant health concern throughout the world.
Standard therapy for advanced disease consists of anti-androgens, however, almost all …

Inflammation plays a central role in prostate cancer (PCa) development through significant
crosstalk between the COX-2-ErbB family receptor network and androgen receptor (AR) …

Background: Non-steroidal anti-inflammatory drugs inhibit the activity of cyclooxygenases
(COXs), and their usage reduces the risks associated with prostate cancer. Celecoxib is a …

Recent work suggests the selective Cox-2 inhibitor celecoxib delays progression to
androgen independence in hormone sensitive prostate cancer (HSPC) through inhibition of …

Background Chronic inflammation has been implicated in cancer etiology and angiogenesis
is stimulated in this disease. In prostate, the crosstalk between malignant epithelial cells and …

BACKGROUND Hormonal ablation is the standard of treatment for advanced androgen‐
dependent prostate cancer. Although tumor regression is usually achieved at first, the …

Abstract Background Prostate cancer (PCa) is the most common malignant tumor in
developed countries, which has seriously threatened men's lifestyle and quality of life. The …

Previous studies showed that CXCR7 expression was upregulated after enzalutamide (ENZ)
treatment, and an increased level of CXCR7 could increase the invasion, migration, and …

Background: We performed a pilot study, looking at the COX-2 inhibitor celecoxib, on newly
diagnosed prostate cancer patients in the neo-adjuvant setting using DNA microarray …

To understand the organization of the biological networks that might potentially govern the
pathogenesis of hormone refractory prostate cancer (HRPC), we investigated the …